Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Tisagenlecleucel

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 7Kymriah

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Kymriah

    Tisagenlecleucel

    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Kymriah

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis

    Tisagenlecleucel

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 474

    2019 Revenue in Millions : 278

    Growth (%) : 71

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Kymriah

    Tisagenlecleucel

    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Kymriah

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis

    Tisagenlecleucel

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 587

    2020 Revenue in Millions : 474

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Kymriah

    Tisagenlecleucel

    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Kymriah

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis

    Tisagenlecleucel

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 536

    2021 Revenue in Millions : 587

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Kymriah

    Tisagenlecleucel

    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Kymriah

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis

    Tisagenlecleucel

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 508

    2022 Revenue in Millions : 536

    Growth (%) : -5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Kymriah

    Tisagenlecleucel

    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Kymriah

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis

    Tisagenlecleucel

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 443

    2023 Revenue in Millions : 508

    Growth (%) : -13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Kymriah

    Tisagenlecleucel

    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Kymriah

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis

    Tisagenlecleucel

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 76

    2017 Revenue in Millions : 6

    Growth (%) : 1167%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Kymriah

    Tisagenlecleucel

    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Kymriah

    Switzerland
    arrow
    PEGS Boston Summit
    Not Confirmed

    Novartis

    Tisagenlecleucel

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 278

    2018 Revenue in Millions : 76

    Growth (%) : 266

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.